ZyVersa Therapeutics Inc. (ZVSA)

US · Healthcare · Biotechnology

$0.11+8.08%

Last close · 2026-09-17

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-1.8M

EPS

$-2.56

EPS estimate

$-0.25

EPS came in at -2.56 against a street estimate of -0.25 — a miss of 924.0%.

Market cap

$801,496

Forward P/E

0.0

P/B

0.21

Book value

$-1.75

EPS (TTM)

$-3.67

52-week high

$0.30

52-week low

$0.08

50-day MA

$0.11

200-day MA

$0.17

Beta

0.87

Analysts rate ZyVersa Therapeutics Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $20.00.

Insiders

0.02%

Institutions

5.15%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ZyVersa Therapeutics Inc. — free to start.

Data updated 2026-09-18.